翰宇藥業(300199.SZ):2020年實現扭虧為盈 預盈2000萬元–3000萬元
格隆匯 1 月 30日丨翰宇藥業(300199.SZ)披露2020年年度業績預吿,預計2020年年度歸屬於上市公司股東的淨利潤2000萬元–3000萬元,上年同期虧損8.85億元;扣除非經常性損益後的淨虧損1.8億元–2.4億元,上年同期虧損9.21億元。業績變動原因如下:
1、2020年度,因公司對上海健麾信息技術股份有限公司(“健麾信息”)投資定位的調整,公司對健麾信息的股權核算方法由權益法計量改為公允價值計量,導致投資收益較上年同期有較大幅度的增加;
2、2019年公司對商譽已全額計提減值,2020年無商譽計提影響,故資產減值損失較上年同期有較大幅度的減少;
3、公司預計2020年全年非經常性損益對淨利潤的影響金額為2.1億元到2.6億元之間主要是健麾信息的股權核算方法發生變更。去年同期非經常性損益金額為3658.64萬元。
Follow us
Find us on
Facebook,
Twitter ,
Instagram, and
YouTube or frequent updates on all things investing.Have a financial topic you would like to discuss? Head over to the
uSMART Community to share your thoughts and insights about the market! Click the picture below to download and explore uSMART app!

Disclaimers
uSmart Securities Limited (“uSmart”) is based on its internal research and public third party information in preparation of this article. Although uSmart uses its best endeavours to ensure the content of this article is accurate, uSmart does not guarantee the accuracy, timeliness or completeness of the information of this article and is not responsible for any views/opinions/comments in this article. Opinions, forecasts and estimations reflect uSmart’s assessment as of the date of this article and are subject to change. uSmart has no obligation to notify you or anyone of any such changes. You must make independent analysis and judgment on any matters involved in this article. uSmart and any directors, officers, employees or agents of uSmart will not be liable for any loss or damage suffered by any person in reliance on any representation or omission in the content of this article. The content of the article is for reference only and does not constitute any offer, solicitation, recommendation, opinion or guarantee of any securities, virtual assets, financial products or instruments. Regulatory authorities may restrict the trading of virtual asset-related ETFs to only investors who meet specified requirements. Any calculations or images in the article are for illustrative purposes only.
Investment involves risks and the value and income from securities may rise or fall. Past performance is not indicative of future performance. Please carefully consider your personal risk tolerance, and consult independent professional advice if necessary.